Accueil   Diary - News   All news THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201

THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201

  • This study compares the efficacy of THN201 with the standard-of-care drug in Alzheimer's disease associated neurocognitive disorders

  • Results are expected towards the end of 2019

 

 

 

Lyon, September 17, 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, has announced the inclusion of the last healthy subject in its Phase Ib trial comparing the pharmacological efficacy of its drug candidate THN201 with the standard-of-care treatment in Alzheimer's disease-related neurocognitive disorders.

 

A total of 152 healthy subjects were recruited at 10 sites in Europe. The trial was conducted as a double-blind, randomized, three arms, parallel study to evaluate the pro-cognitive activity, tolerance and pharmacokinetics of THN201 compared with the standard-of-care treatment alone or a placebo. THN201 has already demonstrated a preclinical pharmacological efficacy profile superior to the standard-of-care treatment in Alzheimer's disease and an excellent safety profile.

 

 

 

Read the press release